Private Advisor Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.9M Sell
744,034
-45,018
-6% -$1.18M 0.08% 256
2026
Q1
$22.2M Buy
789,052
+7,340
+0.9% +$195K 0.1% 204
2025
Q4
$19.5M Buy
781,712
+103,296
+15% +$2.6M 0.09% 235
2025
Q3
$17.3M Sell
678,416
-18,679
-3% -$461K 0.09% 241
2025
Q2
$16.9M Sell
697,095
-10,619
-2% -$248K 0.09% 227
2025
Q1
$17.9M Buy
707,714
+42,238
+6% +$1.11M 0.11% 190
2024
Q4
$17.7M Sell
665,476
-184,109
-22% -$4.99M 0.1% 191
2024
Q3
$24.6M Buy
849,585
+113,623
+15% +$3.31M 0.15% 130
2024
Q2
$20.6M Buy
735,962
+83,754
+13% +$2.31M 0.14% 142
2024
Q1
$18.1M Buy
652,208
+81,168
+14% +$2.25M 0.13% 150
2023
Q4
$16.4M Sell
571,040
-19,645
-3% -$594K 0.13% 153
2023
Q3
$19.6M Sell
590,685
-21,889
-4% -$774K 0.18% 116
2023
Q2
$22.4M Buy
612,574
+45,590
+8% +$1.77M 0.19% 104
2023
Q1
$23.1M Sell
566,984
-678
-0.1% -$29.3K 0.22% 98
2022
Q4
$6.46M Sell
567,662
-47,311
-8% -$2.27M 0.33% 61
2022
Q3
$26.9M Sell
614,973
-97,728
-14% -$4.75M 0.31% 69
2022
Q2
$37.4M Buy
712,701
+23,378
+3% +$1.19M 0.33% 60
2022
Q1
$35.7M Sell
689,323
-95,910
-12% -$4.98M 0.27% 73
2021
Q4
$46.4M Sell
785,233
-107,703
-12% -$5.34M 0.35% 56
2021
Q3
$38.4M Buy
892,936
+271,678
+44% +$12M 0.24% 75
2021
Q2
$24.3M Sell
621,258
-56,294
-8% -$2.19M 0.21% 89
2021
Q1
$24.5M Buy
677,552
+52,334
+8% +$1.86M 0.23% 87
2020
Q4
$23M Buy
625,218
+85,876
+16% +$3.15M 0.24% 81
2020
Q3
$18.3M Buy
539,342
+33,663
+7% +$1.18M 0.24% 83
2020
Q2
$15.7M Buy
505,679
+55,106
+12% +$1.87M 0.22% 93
2020
Q1
$14M Sell
450,573
-26,650
-6% -$908K 0.26% 79
2019
Q4
$17.7M Sell
477,223
-46,926
-9% -$1.67M 0.28% 76
2019
Q3
$18M Buy
524,149
+101,062
+24% +$3.67M 0.28% 74
2019
Q2
$17.4M Buy
423,087
+5,608
+1% +$223K 0.31% 61
2019
Q1
$16.7M Buy
417,479
+15,625
+4% +$626K 0.33% 58
2018
Q4
$16.6M Sell
401,854
-24,205
-6% -$1M 0.4% 43
2018
Q3
$17.8M Buy
426,059
+128,383
+43% +$4.94M 0.37% 52
2018
Q2
$10.3M Buy
297,676
+89,322
+43% +$3.05M 0.17% 51
2018
Q1
$7.02M Sell
208,354
-75,023
-26% -$2.58M 0.27% 81
2017
Q4
$9.79M Sell
283,377
-160,443
-36% -$5.47M 0.41% 49
2017
Q3
$15.2M Buy
443,820
+7,234
+2% +$232K 0.38% 51
2017
Q2
$13.8M Sell
436,586
-15,546
-3% -$490K 0.37% 54
2017
Q1
$13.8M Buy
452,132
+19,644
+5% +$619K 0.39% 51
2016
Q4
$13.5M Buy
432,488
+37,770
+10% +$1.15M 0.44% 47
2016
Q3
$12.6M Sell
394,718
-16,791
-4% -$561K 0.52% 37
2016
Q2
$14M Buy
411,509
+47,809
+13% +$1.53M 0.57% 36
2016
Q1
$10.3M Sell
363,700
-2,387
-0.7% -$68.2K 0.5% 38
2015
Q4
$11.2M Buy
366,087
+25,346
+7% +$797K 0.54% 35
2015
Q3
$10.2M Buy
340,741
+49,694
+17% +$1.59M 0.56% 32
2015
Q2
$9.26M Sell
291,047
-817
-0.3% -$26.6K 0.44% 43
2015
Q1
$9.63M Buy
291,864
+35,992
+14% +$1.14M 0.56% 28
2014
Q4
$7.53M Buy
255,872
+40,751
+19% +$1.17M 0.49% 42
2014
Q3
$6.04M Buy
215,121
+24,602
+13% +$690K 0.42% 48
2014
Q2
$5.37M Buy
190,519
+12,979
+7% +$370K 0.46% 45
2014
Q1
$5.41M Buy
177,540
+49,389
+39% +$1.47M 0.57% 30
2013
Q4
$3.72M Buy
+128,151
New +$3.73M 0.42% 48

Other funds holding PFE

Private Advisor Group's PFE Position: Q2 2026 in Review

Private Advisor Group reduced its Pfizer (PFE) stake by 5.7% in Q2 2026, selling an estimated $1.18M and leaving 744,034 shares worth $17.9M. The position accounts for 0.08% of the portfolio, ranked #256.

Private Advisor Group first reported a position in PFE in Q4 2013 and has held it in 51 quarters since. The position peaked at $46.4M in Q4 2021. 1,179 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Private Advisor Group held 744,034 shares of Pfizer worth $17.9M as of Q2 2026.
  • Private Advisor Group sold 45,018 Pfizer shares in Q2 2026, an estimated $1.18M.
  • Pfizer made up 0.08% of Private Advisor Group's portfolio in Q2 2026, its #256 holding.
  • Private Advisor Group first reported a position in Pfizer in Q4 2013 and has held it in 51 quarters since.
  • Private Advisor Group's Pfizer position peaked at $46.4M in Q4 2021.
  • 1,179 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.